ImmunoGen Inc (IMGN)

[skitahoe]

In the IMGN conference call yesterday they indicated that later this year they'll approach the European authorities to discuss the potential of approval there based on the Phase 3 Trial. In that IMGN has always indicated an intent to do a ROW partnership and not market outside of North America, or possibly just the U.S. themselves, it would make sense for them to make that partnership with BP before approaching the European authorities.

At this point they know what the drug does, they know it can obtain approvals in the right platinum resistant group, and it still may be expanded to other cancers with similar platinum resistance. A potential partner certainly won't pay as much as they would have had the Phase 3 Trial been successful, but they still should be willing to pay substantially for a drug that should be approved in the U.S. and a few years, and could possibly be approved where they'll have the rights much sooner.

I'm not saying this will happen, but it's a strategy that would assure IMGN the funds needed for all the trials it has underway without massive dilution, and it would have the European authorities, and others, working with a BP who already has a presents in their country.

Gary